Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Henry Schein    HSIC

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Henry Schein : Kessler Topaz Meltzer & Check, LLP Reminds Henry Schein, Inc. Shareholders of Important Deadline in Class Action Lawsuit

share with twitter share with LinkedIn share with facebook
share via e-mail
03/22/2018 | 04:32pm CET

RADNOR, PA / ACCESSWIRE / March 22, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Henry Schein, Inc. (NASDAQ: HSIC) ("Henry Schein" or the "Company") on behalf of purchasers of the Company's securities between March 7, 2013 and February 12, 2018, inclusive (the "Class Period").

Deadline Reminder: Investors who purchased Henry Schein securities during the Class Period may, no later than May 7, 2018, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action please visit https://www.ktmc.com/new-cases/henry-schein-inc#join.

Henry Schein provides health care products and services to medical and dental practitioners.

On February 12, 2018, the Federal Trade Commission ("FTC") issued a press release entitled "FTC Sues Dental Products Distributors for Alleged Conspiracy Not to Provide Discounts to a Customer Segment." Therein the FTC disclosed that it had filed a complaint against Henry Schein, and certain other dental supply companies, alleging "that they violated U.S. antitrust laws by conspiring to refuse to provide discounts to or otherwise serve buying groups representing dental practitioners."

Following this news, shares of Henry Schein's common stock fell $4.79 per share, or over 6.6%, to close on February 13, 2018 at $67.39, on heavy trading volume.

The shareholder class action complaint alleges that Henry Schein and certain of its senior executive officers made false and misleading statements and/or failed to disclose to investors that: (1) Henry Schein was engaging in unethical, anti-competitive behavior through agreements with Benco Dental Supply Company and Patterson Companies, Inc., in violation of U.S. antitrust laws; (2) Henry Schein engaged in such behavior, in part, to help maintain profitability in a consolidating health care industry; (3) these violations of U.S. antitrust laws would result in heightened scrutiny by the federal government and a lawsuit filed by the FTC; (4) Henry Schein failed to maintain adequate internal controls; and (5) as a result of the foregoing, the defendants' statements about Henry Schein's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Henry Schein shareholders may, no later than May 7, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.


Kessler Topaz Meltzer & Check, LLP
Darren J. Check, Esq.
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
[email protected]

SOURCE: Kessler Topaz Meltzer & Check, LLP

© Accesswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on HENRY SCHEIN
04:32pHENRY SCHEIN : Kessler Topaz Meltzer & Check, LLP Reminds Henry Schein, Inc. Sha..
03/20HSIC The Law Offices of Vincent Wong Notifies Investors of a Class Action Inv..
03/19HENRY SCHEIN : The Schall Law Firm Announces the Filing of a Securities Class Ac..
03/19HENRY SCHEIN, INC. (NASDAQ : HSIC) Files An 8-K Departure of Directors or Certai..
03/19HENRY SCHEIN INC : Change in Directors or Principal Officers, Other Events (form..
03/16HENRY SCHEIN : Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exc..
03/16Levi & Korsinsky, LLP Notifies Shareholders of Henry Schein, Inc. of Commence..
03/16HENRY SCHEIN : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Act..
03/15HENRY SCHEIN : Cares Global Student Outreach Program Supports Student-Led Missio..
03/15HSIC LOSS NOTICE : Rosen Law Firm Reminds Henry Schein, Inc. Investors of Import..
More news
News from SeekingAlpha
03/09Key events next week - healthcare (continued #5) 
03/08Premarket analyst action - healthcare 
02/26Tracking Al Gore's Generation Investment Management Portfolio - Q4 2017 Updat.. 
02/21Henry Schein, Inc. 2017 Q4 - Results - Earnings Call Slides 
02/20Henry Schein's CEO Stanley Bergman on (HSIC) Q4 2017 Results - Earnings Call .. 
Financials ($)
Sales 2018 13 299 M
EBIT 2018 921 M
Net income 2018 631 M
Debt 2018 1 236 M
Yield 2018 -
P/E ratio 2018 16,11
P/E ratio 2019 14,77
EV / Sales 2018 0,87x
EV / Sales 2019 0,81x
Capitalization 10 315 M
Duration : Period :
Henry Schein Technical Analysis Chart | HSIC | US8064071025 | 4-Traders
Technical analysis trends HENRY SCHEIN
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 77,8 $
Spread / Average Target 18%
EPS Revisions
Stanley M. Bergman Chairman & Chief Executive Officer
James P. Breslawski President & Director
Steven Paladino Chief Financial Officer, Director & Executive VP
James A. Harding Chief Technology Officer & Senior Vice President
Philip A. Laskawy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
HENRY SCHEIN-5.95%10 315
COLOPLAST A/S2.74%16 649
AMPLIFON SPA9.58%3 935